Entera Bio Ltd. Stock price

Equities

ENTX

IL0011429839

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.67 USD +8.44% Intraday chart for Entera Bio Ltd. -2.91% +178.33%
Sales 2024 * - Sales 2025 * - Capitalization 54.64M
Net income 2024 * -30M Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-2.23 x
P/E ratio 2025 *
-
Employees 18
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.88%
More Fundamentals * Assessed data
Dynamic Chart
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months CI
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Premarket Gainers MT
Top Premarket Gainers MT
Entera Bio Ltd. announced that it has received $6.610594 million in funding CI
Entera Bio Ltd. announced that it expects to receive $6.610594 million in funding CI
Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform CI
Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide Phase 3 Program CI
Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting CI
Entera Bio Ltd. Announces Collaboration with OPKO Biologics, Inc. to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes CI
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research Annual Meeting CI
Entera Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Entera Bio Ltd Adds Haya Taitel to its Board of Directors CI
More news
1 day+8.44%
1 week-2.91%
Current month+21.45%
1 month+33.60%
3 months+203.25%
6 months+132.27%
Current year+178.33%
More quotes
1 week
1.45
Extreme 1.45
1.75
1 month
1.25
Extreme 1.25
1.87
Current year
0.58
Extreme 0.5826
1.87
1 year
0.52
Extreme 0.52
1.87
3 years
0.47
Extreme 0.4722
8.68
5 years
0.00
Extreme 0
10.16
10 years
0.00
Extreme 0
10.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 18-09-26
Director of Finance/CFO 40 19-05-31
Chief Tech/Sci/R&D Officer - 17-12-31
Members of the board TitleAgeSince
Chairman 77 13-12-31
Director/Board Member 70 16-02-29
Director/Board Member 73 19-01-09
More insiders
Date Price Change Volume
24-03-28 1.67 +8.44% 124,686
24-03-27 1.54 -0.65% 41,660
24-03-26 1.55 -0.64% 211,325
24-03-25 1.56 -1.27% 38,651
24-03-22 1.58 -8.14% 398,445

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.67 USD
Average target price
10 USD
Spread / Average Target
+498.80%
Consensus
  1. Stock
  2. Equities
  3. Stock Entera Bio Ltd. - Nasdaq